SELLAS Life Sciences Group, Inc. — Director's Dealing 2012

Jan 17, 2012

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Galena Biopharma, Inc. (GALE)
CIK: 0001390478
Period of Report: 2012-01-12

Reporting Person: SCHWARTZ MARK W. (EVP Chief Operating Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2012-01-12	Stock Option (right to buy)	$0.72	A	200000	Acquired	2022-01-12	Common Stock (200000)	Direct

Footnotes

F1: Granted pursuant to the Issuer's 2007 Incentive Plan.

F2: The options will vest in equal quarterly installments of 12,500 shares for four years beginning on April 12, 2012, with all such options being fully vested on January 12, 2016.